Rigel Pharmaceuticals (RIGL) Gross Margin (2018 - 2026)

Rigel Pharmaceuticals' Gross Margin history runs 9 years deep, the most recent figure standing at 92.17% for Q1 2026.

• In Q1 2026, Gross Margin rose 44.0% year-over-year to 92.17%; the TTM figure through Mar 2026 stood at 93.39% (up 375.0% YoY), while the FY2025 annual figure was 93.33%, up 373.0% from the prior year.
• Gross Margin was 92.17% for Q1 2026 at Rigel Pharmaceuticals, up from 91.47% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 99.33% in Q4 2022 to a low of 85.49% in Q3 2024.
• Historically, Gross Margin has averaged 93.9% across 5 years, with a median of 93.16% in 2025.
• The sharpest annual moves came in 2024 and 2025: Gross Margin tumbled 1000 bps in 2024, then surged 767 bps in 2025.
• A 5-year view of Gross Margin shows it stood at 99.33% in 2022, then decreased by 10 bps to 89.41% in 2023, then climbed by 1 bps to 89.95% in 2024, then gained by 2 bps to 91.47% in 2025, then gained by 1 bps to 92.17% in 2026.
• The last three Gross Margin figures came in at 92.17% (Q1 2026), 91.47% (Q4 2025), and 93.16% (Q3 2025), per Business Quant data.